MK0767 + metformin

MK0767 + metformin is a combination of two agents used for the treatment of type 2 diabetes mellitus. MK0767 is an investigational compound developed by Merck Sharp & Dohme for the management of type 2 diabetes, with clinical studies assessing its glucose-lowering and lipid-lowering efficacy in comparison to metformin monotherapy[3][4]. Metformin is a well-established antihyperglycemic small molecule that works primarily by reducing hepatic glucose production and improving insulin sensitivity in peripheral tissues. The combination is considered experimental, as clinical studies have tested the parallel effects of MK0767 against metformin rather than as a fixed-dose combination. Both components function via distinct mechanisms to improve glycemic control in diabetic patients.